- Cerebral Oximetry Added to STS National Database
Branford, CT – February 6, 2008 – CAS Medical Systems, Inc. (NASDAQ: CASM), a medical device company focused on innovative, non-invasive vital signs monitoring, today announced the placement of its fiftieth revenue-generating FORE-SIGHT monitor in North America. The FORE-SIGHT monitor, which non-invasively and continuously measures absolute cerebral tissue oxygen saturation, was commercially introduced mid-2007.
Andrew E. Kersey, President and CEO of CASMED, commented, “Reaching the milestone of the 50th unit is an important indication of our initial success in penetrating the cerebral oximetry market. These placements represent over twenty institutions in North America, all of which are generating income from sales of sensors. In addition, a number of monitors are in the field undergoing clinical evaluations by customers as we continue to see strong interest in the FORE-SIGHT solution. We have made significant inroads both with customers who are new to cerebral oximetry, and with past users of cerebral oximetry, who have moved to our technology based on their recognition of the importance of the absolute saturation values provided by CASMED’s advanced LASER-SIGHT® Optical Technology.”
The Company reports that clinical studies are on-going at various locations throughout North America. For the adult population, studies targeting aortic, thoracic, orthopedic and general surgeries are underway. Enrollment for the 60 patient CABG surgery study at Duke University Medical Center is now complete and results from this study are expected later this year. Additionally, the Company is participating in a new NIH-funded major multi-center study researching cognitive decline and delirium in elderly patients undergoing major general surgery. Customer preference testing is also underway at five key infant / neonatal clinical locations throughout the US to support the launch of the infant / neonatal sensor later this year. In Europe, we are planning to complement the FORE-SIGHT product launch by establishing two adult clinical research / reference sites.
The Company also announced the acceptance for publication of a cerebral oximetry review paper to be published in Seminars in Cardiothoracic and Vascular Anesthesia. The publication, entitled “Recent Advances in the Application of Cerebral Oximetry in Adult Cardiovascular Surgery”, was authored by Gregory W. Fischer, M.D., Co-Director of Cardiac Anesthesia at Mount Sinai Medical Center in New York. It reviews the development of cerebral oximetry technology, and evaluates his experience with currently available monitoring devices.
In addition, CASMED reports that FORE-SIGHT has received considerable attention at the Society of Thoracic Surgeons (STS) meeting in Fort Lauderdale, Florida this week. Beginning last month, the STS National Database of outcomes in the areas of adult cardiac, general thoracic and congenital surgeries will be including cerebral oximetry measurements as part of their metrics. The Company believes that the inclusion of cerebral oximetry in this database elevates the importance and general awareness of the parameter and forwards the efforts to make cerebral oximetry monitoring a standard of care in these surgical cases.
About the FORE-SIGHT Absolute Cerebral Oximeter
FORE-SIGHT provides clinically relevant absolute measurements that indicate a patient’s cerebral tissue oxygen saturation status. CASMED’s initial market focus for the FORE-SIGHT product is on high risk cardiovascular surgeries, of which there are about 700,000 performed each year in the U.S. Additional market opportunities include a broad range of general surgical procedures and post-operative and critical care settings. Protecting the brain from low oxygen levels during these procedures is an important goal of every surgical team because the brain is highly vulnerable to oxygen deprivation. At normal body temperatures, damage to brain cells due to lack of oxygen can occur after just a few seconds. The FORE-SIGHT Cerebral Oximeter provides new information that allows clinicians to monitor and respond to instances of brain tissue oxygen deprivation before damage to the brain occurs.
About CASMED®
Founded in 1984, CAS Medical Systems, Inc. is dedicated to the design and manufacture of innovative technologies and products vital to patient care in the most challenging clinical environments. Its current product lines include cerebral oximeters, blood pressure measurement technology, vital signs monitoring equipment, blood pressure cuffs, cardio-respiratory and apnea monitoring equipment and products for neonatal intensive care. With a reputation for the highest quality products available in the markets it serves, CASMED products are used by clinicians worldwide.
For further information regarding CAS Medical Systems, Inc., visit the Company’s website at www.casmed.com.
Company Contacts
CAS Medical Systems, Inc.
Susan Carron
Director of Corporate Communications
203-488-6056
ir@casmed.com
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, commercialization and technological difficulties, the impact of any adverse litigation and other risks detailed in the Company’s most recent Form 10-KSB and other Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise
